Recommendations and guidance on the diagnosis and management of Danon disease

References

• D’souza RS, Mestroni L, Taylor MRG. Danon disease for the cardiologist: case report and review of the literature. J Community Hosp Intern Med Perspect. 2017;7(2):107–114.
   PubMed Web of Science ®Google Scholar
• Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112:1612–1617.
   PubMed Web of Science ®Google Scholar
• Cenacchi G, Papa V, Pegoraro V, et al. Review: Danon disease: review of natural history and recent advances. Neuropathol Appl Neurobiol. 2020;46(4):303–322.
   PubMed Web of Science ®Google Scholar
• Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13(6):563–568.
   PubMed Web of Science ®Google Scholar
• Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362‐372.
   PubMed Web of Science ®Google Scholar
• Charron P, Villard E, Sébillon P, et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842–846.
   PubMed Web of Science ®Google Scholar
• Endo Y, Furuta A, Nishino I. Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta Neuropathol. 2015;129(3):391–398.
   PubMed Web of Science ®Google Scholar
• Germain DP. General aspects of X-linked diseases. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis. 2006. Chapter 7. Available from:. https://www.ncbi.nlm.nih.gov/books/NBK11593/
   Google Scholar
• Taylor M, Adler E. Danon disease. GeneReviews® [Internet]. 2020. p. 1–20. [cited 2021 Jan 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554742/
   Google Scholar
• Nascimbeni AC, Fanin M, Angelini C, et al. Autophagy dysregulation in Danon disease. Cell Death Dis. 2017 Jan 19;8(1):e2565.
   PubMedGoogle Scholar
• Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000;406(6798):906–910.
   PubMed Web of Science ®Google Scholar
• Rowland TJ, Sweet ME, Mestroni L, et al. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci. 2016;129(11):2135–2143.
   PubMed Web of Science ®Google Scholar
• Sugie K, Komaki H, Eura N, et al. A nationwide survey on danon disease in Japan. Int J Mol Sci. 2018;19(11):1–14.
   Web of Science ®Google Scholar
• Hashem SI, Murphy AN, Divakaruni AS, et al. Impaired mitophagy facilitates mitochondrial damage in Danon disease. J Mol Cell Cardiol. 2017;108:86–94.
   PubMed Web of Science ®Google Scholar
• D’souza RS, Levandowski C, Slavov D, et al. Danon disease clinical features, evaluation, and management. Circ Hear Fail. 2014;7(5):843–849.
   PubMed Web of Science ®Google Scholar
• Hedberg Oldfors C, Máthé G, Thomson K, et al. Early onset cardiomyopathy in females with Danon disease. Neuromuscul Disord. 2015;25(6):493–501.
   PubMed Web of Science ®Google Scholar
• Brambatti M, Caspi O, Maolo A, et al. Danon disease: gender differences in presentation and outcomes. Int J Cardiol. 2019;286:92–98.
   PubMed Web of Science ®Google Scholar
• Samad F, Jain R, Jan MF, et al. Malignant cardiac phenotypic expression of Danon disease (LAMP-2 cardiomyopathy). Int J Cardiol. 2017;245:201–206.
   PubMed Web of Science ®Google Scholar
• Jhaveri S, Herber J, Zahka K, et al. Arrhythmias and fasciculoventricular pathways in patients with Danon disease: a single center experience. J Cardiovasc Electrophysiol. 2019;30(10):1932–1938.
   PubMed Web of Science ®Google Scholar
• Taylor MRG, Ku L, Slavov D, et al. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet. 2007;52(10):830–835.
   PubMed Web of Science ®Google Scholar
• Bottillo I, Giordano C, Cerbelli B, et al. A novel LAMP-2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. Cardiovasc Pathol. 2016;25(5):423–431.
   PubMed Web of Science ®Google Scholar
• Brooks M, Ma GS, Darden D, et al. Wolff-Parkinson-white in individuals with Danon disease is a marker of higher severity disease. Am Coll Cardiol. 2020 Mar;75:843.
   Web of Science ®Google Scholar
• López-Sainz Á, Salazar-Mendiguchía J, García-Álvarez A, et al. Clinical findings and prognosis of Danon disease. an analysis of the Spanish multicenter danon registry. Rev Esp Cardiol (Engl Ed). 2019 June;72(6):479–486.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP-2 cardiomyopathy. J Am Med Assoc. 2009;301(12):1253–1259.
   Web of Science ®Google Scholar
• Poignant S, Bourguignon T, Espitalier F. Heart transplantation in Danon disease: a single family displaying diverse phenotypes. J Heart Lung Transplant. 2018;37(2):312‐313.
   Web of Science ®Google Scholar
• Oren D, Chau P, Manning M, et al. Heart transplantation in two adolescents with Danon disease. Pediatr Transplant. 2019 Mar;23(2):e13335.
   PubMed Web of Science ®Google Scholar
• Yardeni M, Weisman O, Mandel H, et al. Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP-2 gene mutation). Am J Med Genet A. 2017 Sept;173(9):2461–2466.
   PubMed Web of Science ®Google Scholar
• Spinazzi M, Fanin M, Melacini P, et al. Cardioembolic stroke in Danon disease. Clinical. 2008;73(4):388–390.
   Google Scholar
• Tsuda T, Shillingford AJ, Vetter J, et al. Transient ischemic attack and ischemic stroke in Danon disease with formation of left ventricular apical thrombus despite normal systolic function. Case Rep Pediatr. 2017;2017:6576382.
   PubMed Web of Science ®Google Scholar
• Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American college of medical genetics and genomics. Genet Med. 2017 Feb;19(2):249–255.
   PubMed Web of Science ®Google Scholar
• Manso AM, Hashem SI, Nelson BC, et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease. Sci Transl Med. 2020 Mar 18;12(535):eaax1744.
   PubMed Web of Science ®Google Scholar
• Hashem SI, Perry CN, Bauer M, et al. Brief report: oxidative stress mediates cardiomyocyte apoptosis in a human model of Danon disease and heart failure. Stem Cells. 2015 July;33(7):2343–2350.
   PubMed Web of Science ®Google Scholar
• Ng KM, Mok PY, Butler AW, et al. Amelioration of X-linked related autophagy failure in danon disease with DNA methylation inhibitor. Circulation. 2016 Nov 1;134(18):1373–1389.
   PubMed Web of Science ®Google Scholar
• Fanin M, Nascimbeni AC, Fulizio L, et al. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol. 2006 Apr;168(4):1309–1320.
   PubMed Web of Science ®Google Scholar
• Bui QM, Hong KN, Kraushaar M, et al. Apical sparing strain pattern in Danon disease: insights from a global registry. JACC Cardiovasc Imaging. 2020 Dec;13(12):2689–2691.
   PubMed Web of Science ®Google Scholar
• Esposito R, Galderisi M, Santoro C, et al. Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naive Anderson-Fabry disease patients. Eur Heart J Cardiovasc Imaging. 2019;20:438–445.
   PubMed Web of Science ®Google Scholar
• Pagourelias ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10:e005588.
   PubMed Web of Science ®Google Scholar
• Liu D, Hu K, Nordbeck P, et al. Longitudinal strain bull’s eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy. Eur J Med Res. 2016;21:21.
   PubMed Web of Science ®Google Scholar
• Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442–1448.
   PubMed Web of Science ®Google Scholar
• Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(10):1180–1193.
   PubMed Web of Science ®Google Scholar
• Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855–861.
   PubMed Web of Science ®Google Scholar
• Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014 Aug 5;130(6):484–495.
   PubMed Web of Science ®Google Scholar
• Moon JCC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003 Dec;24(23):2151–2155.
   PubMed Web of Science ®Google Scholar
• Musa TA, Treibel TA, Vassiliou VS, et al. Myocardial scar and mortality in severe aortic stenosis: data from the BSCMR valve consortium. Circulation. 2018 Oct 30;138(18):1935–1947.
   PubMed Web of Science ®Google Scholar
• McCrohon JA, Moon JCC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003 July 8;108(1):54–59.
   PubMed Web of Science ®Google Scholar
• Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013 Mar 6;309(9):896–908.
   PubMed Web of Science ®Google Scholar
• Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease. J Am Coll Cardiol. 2019 Feb;73(4):488–516.
   PubMed Web of Science ®Google Scholar
• Piotrowska-Kownacka D, Kownacki L, Kuch M, et al. Cardiovascular magnetic resonance findings in a case of Danon disease. J Cardiovasc Magn Reson. 2009 Dec;11(1):12.
   PubMedGoogle Scholar
• Tada H, Harimura Y, Yamasaki H, et al. Utility of real-time 3-dimensional echocardiography and magnetic resonance imaging for evaluation of danon disease. Circulation. 2010 May 4;121(17). DOI:10.1161/CIR.0b013e3181de7097
   PubMed Web of Science ®Google Scholar
• Vago H, Somloi M, Toth A, et al. Danon disease: a rare cause of left ventricular hypertrophy with cardiac magnetic resonance follow-up. Eur Heart J. 2016 June 1;37(21):1703.
   PubMed Web of Science ®Google Scholar
• Rigolli M, Kahn AM, Brambatti M, et al. Cardiac magnetic resonance imaging in danon disease cardiomyopathy. JACC Cardiovasc Imaging. 2020 Sept 26:S1936-878X(20)30728–2. DOI:10.1016/j.jcmg.2020.08.011
   PubMedGoogle Scholar
• Rigolli M, Kahn A, Brambatti M, et al. Cardiomyopathy characterization and risk-stratification by cardiac magnetic resonance in Danon disease. J Am Coll Cardiol. 2020 Mar 24;75(11 Supplement 1):1681.
   Web of Science ®Google Scholar
• Le DD, Alvarez P, Barrios R, et al. Hypertrophic cardiomyopathy with unusual extensive scarring pattern: Danon disease. Methodist Debakey Cardiovasc J. 2016;12(4):227–229.
   PubMedGoogle Scholar
• Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655–668.
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142(6):e153–e203.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Hear Rhythm. 2016;13(5):1155–1165.
   PubMed Web of Science ®Google Scholar
• Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014 May 1;113(9):1550–1555.
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2018 Oct;15(10):e73–e189.
   PubMed Web of Science ®Google Scholar
• Miani D, Taylor M, Mestroni L, et al. Sudden death associated with Danon disease in women. Am J Cardiol. 2012;109(3):406–411.
   PubMed Web of Science ®Google Scholar
• Zaki A, Zaidi A, Newman WG, et al. Advantages of a subcutaneous implantable cardioverter-defibrillator in LAMP-2 hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2013;24(9):1051–1053.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Fang Q. Danon disease: focusing on heart. J Hum Genet. 2012;57(7):407–410.
   PubMed Web of Science ®Google Scholar
• Cohn LH, Trehan H, Collins JJ. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1992;70(6):657–660.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol. 2016 Sept 27;68(13):1476–1488.
   PubMed Web of Science ®Google Scholar
• Bozkurt B. What is new in heart failure management in 2017? Update on ACC/AHA heart failure guidelines. Curr Cardiol Rep. 2018;20(6). DOI:10.1007/s11886-018-0978-7
   PubMed Web of Science ®Google Scholar
• Hong KN, Battikha C, Lin A. Cardiac transplantation in Danon disease. Int Soc Heart Lung Transplant. 2021 April. DOI:10.1097/TP.0000000000003647
   Google Scholar
• Lotan D, Salazar-Mendiguchía J, Mogensen J, et al. Clinical profile of cardiac involvement in danon disease: a multicenter European registry. Circ Genomic Precis Med. 2020 Nov 5;660–670. DOI:10.1161/CIRCGEN.120.003117
   Web of Science ®Google Scholar
• Thakur R, Afzal A, Carey SA, et al. Repeat cardiac transplant indicated by severe cardiac allograft vasculopathy in a patient with Danon disease. Rev Cardiovasc Med. 2018;19(2):69–71.
   PubMed Web of Science ®Google Scholar